Celldex Therapeutics (CLDX) Receivables - Net (2010 - 2026)

Celldex Therapeutics' Receivables - Net history runs 17 years deep, the most recent figure standing at $230000.0 for Q1 2026.

• In Q1 2026, Receivables - Net fell 78.38% year-over-year to $230000.0; the TTM figure through Mar 2026 stood at $230000.0 (down 78.38% YoY), while the FY2025 annual figure was $2.0 million, up 187.86% from the prior year.
• Receivables - Net for Q1 2026 stood at $230000.0, down from $2.0 million in the prior quarter.
• The five-year high for Receivables - Net was $2.7 million in Q1 2024, with the low at $90000.0 in Q2 2025.
• The 5-year median for Receivables - Net is $247500.0 (2022), against an average of $768500.0.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net surged 1200.0% in 2024, then plunged 94.13% in 2025.
• Celldex Therapeutics' Receivables - Net stood at $189000.0 in 2022, then jumped by 33.33% to $252000.0 in 2023, then soared by 238.1% to $852000.0 in 2024, then soared by 136.5% to $2.0 million in 2025, then sank by 88.59% to $230000.0 in 2026.
• Business Quant data shows CLDX's Receivables - Net at $230000.0 in Q1 2026, $2.0 million in Q4 2025, and $90000.0 in Q3 2025.